1. Home
  2. LEA vs IMVT Comparison

LEA vs IMVT Comparison

Compare LEA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lear Corporation

LEA

Lear Corporation

HOLD

Current Price

$137.61

Market Cap

6.3B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$28.98

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEA
IMVT
Founded
1917
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.8B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
LEA
IMVT
Price
$137.61
$28.98
Analyst Decision
Buy
Buy
Analyst Count
14
8
Target Price
$132.21
$33.00
AVG Volume (30 Days)
530.0K
1.5M
Earning Date
05-01-2026
05-28-2026
Dividend Yield
2.49%
N/A
EPS Growth
N/A
N/A
EPS
3.34
N/A
Revenue
$23,259,100,000.00
N/A
Revenue This Year
$2.50
N/A
Revenue Next Year
$3.12
N/A
P/E Ratio
$41.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$86.14
$13.52
52 Week High
$142.84
$30.09

Technical Indicators

Market Signals
Indicator
LEA
IMVT
Relative Strength Index (RSI) 64.69 58.77
Support Level $115.63 $24.97
Resistance Level $142.84 $29.67
Average True Range (ATR) 4.46 1.48
MACD 1.16 0.01
Stochastic Oscillator 85.48 70.43

Price Performance

Historical Comparison
LEA
IMVT

About LEA Lear Corporation

Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: